Subgroup ————————————————————————————————————	Chemotherapy	Observation	HR	95% CI	Favors Chemotherapy	Favors observation
Age						
< 50	86	94	0.57	(0.39 - 0.84)	-	
≥50	90	82	0.54	(0.36-0.81)	-	
ECOG-PS						
0-1	163	157	0.55	(0.40 - 0.74)	-	
2	13	19	0.60	(0.25-1.42)	-	_
Menopausal status						
Pre	101	96	0.63	(0.44-0.92)	-	
Post	75	80	0.44	(0.29 - 0.68)	-	
Ki67 status						
<14	29	19	0.46	(0.19-1.09)		<del> </del>
≥14	110	95	0.59	(0.41-0.86)	-	
Bone metastasis						
Yes	101	101	0.48	(0.33-0.69)	-	
No	75	75	0.70	(0.44-1.11)	-	
Liver metastasis						
Yes	57	49	0.44	(0.28 - 0.70)	-	
No	119	127	0.58	(0.41-0.83)	-	
Pulmonary metastasis						
Yes	55	62	0.40	(0.24-0.66)	-	
No	121	114	0.65	(0.46-0.92)	-	
Brain metastasis						
Yes	6	14	0.06	(0.01 - 0.40)		
No	170	162	0.60	(0.45-0.81)	-	
Soft tissue metastasis						
Yes	10	6	0.50	(0.14-1.79)		_
No	69	60	0.42	(0.23-0.75)	-	
Lymph node metastasis	i					
Yes	67	68	0.58	(0.36-0.93)	-	
No	109	108	0.54	(0.38-0.77)	=	
Number of metastases						
1 or 2	131	131	0.65	(0.46 - 0.91)	-	
≥3	45	45	0.34	(0.20 - 0.58)	-	
Best response to first-lin	ne systemic treatme	nt				
Objective respond	82	94	0.57	(0.37 - 0.88)	-	
Stable disease	94	82	0.54	(0.37-0.78)	-	
Overall	176	176	0.55	(0.42-0.73)	<del></del>	
	170	1,0	-	/		
					0.01 0.1	1 10

**S5 Fig.** Subgroup analysis between chemotherapy maintenance and observation in multicenter cohort. CI, confidence interval; HR, hazard ratio.